Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China, has announced its participation in a USD 78 million Series E funding round for ZAP Surgical Systems, Inc., a globally recognized leader in non-invasive robotic brain surgery. The investment will support the commercialization efforts of ZAP’s groundbreaking ZAP-X Gyroscopic Radiosurgery platform.
Financing and Commercialization Agreement
The financing round will be instrumental in bolstering the commercialization of the ZAP-X platform, which is designed to treat brain tumors, lesions, and other head and neck conditions through non-invasive procedures. Concurrently, Baheal Pharmaceutical Group and ZAP Surgical Systems have entered into a commercialization agreement that grants Baheal Pharma the exclusive agency rights for the ZAP-X system and its accessory “megavolt scintillation detector” in China, Hong Kong, and Macau.
ZAP-X Gyroscopic Radiosurgery Platform Approval and Impact
The ZAP-X Gyroscopic Radiosurgery platform received marketing approval in China in June 2023, signifying a significant milestone for the advancement of non-invasive brain surgery technologies in the country. This approval paves the way for broader access to ZAP’s innovative treatment options for patients in need of brain and head-related surgical interventions.-Fineline Info & Tech
Leave a Reply